

# Enli Liu

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4444441/enli-liu-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

59  
papers

8,018  
citations

27  
h-index

59  
g-index

59  
ext. papers

9,491  
ext. citations

7.7  
avg, IF

5.21  
L-index

#	Paper	IF	Citations
59	Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30 Malignancies. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3744-3756	12.9	7
58	Metabolic Reprogramming of GMP Grade Cord Tissue Derived Mesenchymal Stem Cells Enhances Their Suppressive Potential in GVHD. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 631353	8.4	3
57	Targeting the $\alpha$ integrin/TGF- $\beta$ axis improves natural killer cell function against glioblastoma stem cells. <i>Journal of Clinical Investigation</i> , <b>2021</b> , 131,	15.9	17
56	Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. <i>Blood</i> , <b>2021</b> , 137, 624-636	2.2	60
55	GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 626098	8.4	6
54	Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 545-553	59.2	652
53	Farrerol Directly Targets GSK-3 to Activate Nrf2-ARE Pathway and Protect EA.hy926 Cells against Oxidative Stress-Induced Injuries. <i>Oxidative Medicine and Cellular Longevity</i> , <b>2020</b> , 2020, 5967434	6.7	14
52	Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cells. <i>Blood Advances</i> , <b>2020</b> , 4, 3357-3367	7.8	13
51	Farrerol maintains the contractile phenotype of VSMCs via inactivating the extracellular signal-regulated protein kinase 1/2 and p38 mitogen-activated protein kinase signaling. <i>Molecular and Cellular Biochemistry</i> , <b>2020</b> , 475, 249-260	4.2	3
50	Next Generation CRISPR Gene-Edited and Off-the-Shelf Virus-Specific T-Cells for the Immunocompromised Patient. <i>Blood</i> , <b>2019</b> , 134, 1944-1944	2.2	
49	Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , <b>2017</b> , 177, 457-466	4.5	100
48	A subset of virus-specific CD161 T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML. <i>Blood</i> , <b>2017</b> , 129, 740-758	2.2	16
47	The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1773	8.4	20
46	Engineering Natural Killer Cells for Cancer Immunotherapy. <i>Molecular Therapy</i> , <b>2017</b> , 25, 1769-1781	11.7	236
45	A robust, good manufacturing practice-compliant, clinical-scale procedure to generate regulatory T cells from patients with amyotrophic lateral sclerosis for adoptive cell therapy. <i>Cytherapy</i> , <b>2016</b> , 18, 1312-24	4.8	25
44	Opening of the inward rectifier potassium channel alleviates maladaptive tissue repair following myocardial infarction. <i>Acta Biochimica Et Biophysica Sinica</i> , <b>2016</b> , 48, 687-95	2.8	4
43	Clinical responses with T lymphocytes targeting malignancy-associated $\beta$ light chains. <i>Journal of Clinical Investigation</i> , <b>2016</b> , 126, 2588-96	15.9	207

42	Sustained ERK activation-mediated proliferation inhibition of farrerol on human gastric carcinoma cell line by G0/G1-phase cell-cycle arrest. <i>European Journal of Cancer Prevention</i> , <b>2016</b> , 25, 490-9	2	19
41	IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation. <i>Blood</i> , <b>2016</b> , 128, 1346-61	2.2	56
40	Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. <i>Blood</i> , <b>2016</b> , 128, 297-312	2.2	40
39	Chitosan attenuates dibutyltin-induced apoptosis in PC12 cells through inhibition of the mitochondria-dependent pathway. <i>Carbohydrate Polymers</i> , <b>2016</b> , 151, 996-1005	10.3	13
38	Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1688-96 <sup>2.2</sup>	2.2	607
37	Apoptosis induced by farrerol in human gastric cancer SGC-7901 cells through the mitochondrial-mediated pathway. <i>European Journal of Cancer Prevention</i> , <b>2015</b> , 24, 365-72	2	23
36	Ibrutinib Can Modulate the T Cell Response in Chronic Lymphocytic Leukemia By Reducing PD1/PDL1 Interactions. <i>Blood</i> , <b>2015</b> , 126, 1737-1737	2.2	7
35	Cord Blood Derived Natural Killer Cells Engineered with a Chimeric Antigen Receptor Targeting CD19 and Expressing IL-15 Have Long Term Persistence and Exert Potent Anti-Leukemia Activity. <i>Blood</i> , <b>2015</b> , 126, 3091-3091	2.2	7
34	Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. <i>Blood</i> , <b>2014</b> , 123, 3750-9	2.2	381
33	Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. <i>Blood</i> , <b>2014</b> , 124, 2034-45	2.2	145
32	Comparative toxicity and apoptosis induced by diorganotins in rat pheochromocytoma (PC12) cells. <i>Food and Chemical Toxicology</i> , <b>2013</b> , 60, 302-8	4.7	19
31	Concomitant JAK2 V617F-positive polycythemia vera and B-cell chronic lymphocytic leukemia in three patients originating from two separate hematopoietic stem cells. <i>American Journal of Hematology</i> , <b>2013</b> , 88, 157-8	7.1	8
30	Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. <i>Blood</i> , <b>2013</b> , 122, 2965-73	2.2	390
29	Clinical Responses In Patients Infused With T Lymphocytes Redirected To Target Light Immunoglobulin Chain. <i>Blood</i> , <b>2013</b> , 122, 506-506	2.2	6
28	Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. <i>Blood</i> , <b>2011</b> , 118, 6050-6	2.2	813
27	Inducible apoptosis as a safety switch for adoptive cell therapy. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 1673-83	59.2	1031
26	Activation of Wnt signaling arrests effector differentiation in human peripheral and cord blood-derived T lymphocytes. <i>Journal of Immunology</i> , <b>2011</b> , 187, 5221-32	5.3	47
25	CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. <i>Journal of Clinical Investigation</i> , <b>2011</b> , 121, 1822-6	15.9	709

24	An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. <i>Stem Cells</i> , <b>2010</b> , 28, 1107-15	5.8	68
23	Administration of Tumor-Specific Cytotoxic T Lymphocytes Engineered to Resist TGF- $\beta$ to Patients with EBV-Associated Lymphomas. <i>Blood</i> , <b>2010</b> , 116, 560-560	2.2	4
22	The Effects of Co-Stimulatory Endodomains on the Fate of T Cells Expressing a Tumor Directed Chimeric Antigen Receptor (CAR) In Human Subjects with B Cell Malignancies. <i>Blood</i> , <b>2010</b> , 116, 3949-3949	2.2	4
21	Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. <i>Nature Medicine</i> , <b>2008</b> , 14, 1264-70	50.5	919
20	Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera. <i>Clinical Immunology</i> , <b>2007</b> , 122, 279-87	9	24
19	Polycythemia vera is not initiated by JAK2V617F mutation. <i>Experimental Hematology</i> , <b>2007</b> , 35, 32-8	3.1	162
18	In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele. <i>Experimental Hematology</i> , <b>2007</b> , 35, 587-95	3.1	34
17	An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions. <i>Journal of Immunology</i> , <b>2006</b> , 177, 4907-16	5.3	23
16	Hypoxia-inducible factor-1 deficiency results in dysregulated erythropoiesis signaling and iron homeostasis in mouse development. <i>Journal of Biological Chemistry</i> , <b>2006</b> , 281, 25703-11	5.4	162
15	High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension. <i>Blood</i> , <b>2006</b> , 107, 3486-8	2.2	27
14	Tlr4 Is Monoallelically Expressed in Human BFU-E and CFU-E and May Have Application as a Clonality Marker in Hematological Disorders Due to Somatic Mutations in Both Males and Females.. <i>Blood</i> , <b>2006</b> , 108, 3619-3619	2.2	
13	The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis. <i>Blood</i> , <b>2005</b> , 105, 1699-705	2.2	55
12	New onset of myelofibrosis in association with pulmonary arterial hypertension. <i>Annals of Internal Medicine</i> , <b>2005</b> , 143, 466-7	8	23
11	In Vitro Expansion of Polycythemia Vera Progenitors Favors Expansion of Erythroid Precursors without JAK2 V617F Mutation.. <i>Blood</i> , <b>2005</b> , 106, 3506-3506	2.2	2
10	Myelofibrosis in a Patient with Sarcoidosis.. <i>Blood</i> , <b>2005</b> , 106, 4965-4965	2.2	1
9	DNA Sequence of Hemoglobin Chico.. <i>Blood</i> , <b>2005</b> , 106, 3784-3784	2.2	
8	The worldwide distribution of the VHL 598C>T mutation indicates a single founding event. <i>Blood</i> , <b>2004</b> , 103, 1937-40	2.2	61
7	Dysregulation of BMPR2, Arginase II and HMGA2 Expression in Idiopathic Myelofibrosis and Secondary Myelofibrosis.. <i>Blood</i> , <b>2004</b> , 104, 792-792	2.2	1

6	High Peripheral Blood CD34 Count in Patients with Idiopathic Myelofibrosis (IF) Is Not Due to Fibrosis and Altered Marrow Microenvironment.. <i>Blood</i> , <b>2004</b> , 104, 2439-2439	2.2	
5	Novel Unconventional Antigen and Conventional Antigens Elicit Anti-Tumor Humoral Immune Reactions in Response to Interferon- $\alpha$ Therapy.. <i>Blood</i> , <b>2004</b> , 104, 2432-2432	2.2	2
4	Mutations in the VHL gene in sporadic apparently congenital polycythemia. <i>Blood</i> , <b>2003</b> , 101, 1591-5	2.2	126
3	Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. <i>Blood</i> , <b>2003</b> , 101, 3294-301 <sup>2</sup>	2.2	128
2	Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia. <i>American Journal of Human Genetics</i> , <b>2003</b> , 73, 412-9	11	85
1	Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. <i>Nature Genetics</i> , <b>2002</b> , 32, 614-21	36.3	407